

Ref: 113/SE/LC/2024-25

Date: 28/03/2025

To,
**Head, Listing Compliance Department
BSE Limited**
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

**Head, Listing Compliance Department
National Stock Exchange of India Limited**
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051
Scrip Symbol: ENTERO

Scrip Code: 544122

Dear Sir/Madam,

Subject: Update on intimation on acquisition of balance equity shares in Getwell Medicare Solution Private Limited to make it wholly owned subsidiary Company. ("Getwell")

With reference to our letter dated March 08, 2024 bearing ref. no. 08/SE/LC/2023-24 and August 02, 2024 bearing ref. no. 30/SE/LC/2024-25; and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR"), we would like to inform you that Company has acquired balance equity shares from erstwhile promoters of Getwell Medicare Solution Private Limited ("Getwell"), thereby making it a wholly owned subsidiary of the Company.

The details required to be furnished in compliance with Regulation 30 read with Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, as amended, are enclosed as "**Annexure-A**".

This is for your information and records.

Yours Faithfully,
For **Entero Healthcare Solutions Limited**

Sanu Kapoor
**VP-General Counsel, Company Secretary and
Compliance Officer**

Details in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Sr. No.	Particulars	Details
a	Name of the target entity, details in brief such as size, turnover etc.	<p>Name of Target Entity: Getwell Medicare Solution Private Limited (“Getwell”)</p> <p>Turnover: Rs. 1,826.10 millions as on March 31, 2024</p>
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>Getwell is presently a Subsidiary of the Company* (95.20% equity shareholding) and with the present acquisition of balance equity shareholding, Getwell will become Wholly Owned Subsidiary Company.</p> <p>The acquisition is based on terms and conditions of the Share Purchase cum Shareholders’ Agreement.</p> <p>The Promoters / Promoter Group does not have any direct interest in Getwell, other than by virtue of being a subsidiary as mentioned above.</p> <p>The transaction is on arms length basis.</p>
c.	Industry to which the entity being acquired belongs	Getwell operates in same line of business activity i.e. business of distribution of pharmaceuticals, surgicals and other healthcare and allied products.
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Getwell has become wholly-owned Subsidiary of the Company.
e.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable

f.	Indicative time period for the completion of the acquisition;	Not Applicable (Acquisition was Completed on March 28, 2025)	
G.	Consideration whether cash consideration or share swap or any other form and details of the same	Consideration was paid in Cash	
h.	Cost of acquisition and/ or the price at which the shares are acquired;	Approximately INR 1,50,00,000/- (Rupees One Crore Fifty Lakhs Only)	
i	Percentage of shareholding / control acquired and/ or number of shares acquired;	12,00,000 equity shares of face value of Rs. 10/- each constituting 4.80% of the paid up equity share capital of Getwell	
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Getwell was incorporated on November 22, 2018 under jurisdiction of Registrar of Companies Ernakulam, Kerala.	
		Getwell operates in same line of business activity i.e. business of distribution of pharmaceuticals, surgicals and other healthcare and allied products majorly in South region of India.	
		Year	Turnover (Rs. in million)
		2023-24	1826.10
		2022-23	1,941.64
2021-22	1,577.13		

***Note:** Reference is drawn to our letter dated 06/03/2025 bearing reference no 109/SE/LC/2024-25, under which Getwell had allotted equity shares on rights basis to existing equity shareholders in March 2025 and pursuant to the said rights issue, percentage of equity shareholding of the Company in Getwell increased from (85%) to (95.20%).